What Is Veppanu, and Why Does It Matter?
Veppanu (vepdegestrant) is an oral cancer medicine for adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), and ESR1‑mutated advanced or metastatic breast cancer. It is used when the cancer has grown after giving at least one hormone (endocrine) therapy. An FDA‑authorized test must first show an ESR1 mutation before you can start treatment. You take it once a day with food. Veppanu is a targeted protein degrader. It brings the estrogen receptor together with a cell protein called cereblon. That pairing labels the receptor for removal by the cell’s cleanup system, lowering estrogen receptor levels in breast cancer cells. This approval is notable because it is the first FDA‑approved proteolysis targeting chimera (PROTAC) therapy, a type of protein degrader designed to clear disease‑driving proteins rather than just block them. Many ER+ breast cancers rely on estrogen signals to grow. After hormone therapy plus a CDK4/6 inhibitor, ESR1 mutations can appear and make standard hormone treatments less effective. The manufacturer reports that about 40%‑50% of people treated this way have ESR1 mutations, which can limit options. Veppanu offers a targeted approach for tumors with this change.
Why Was It Approved?
The FDA based its decision on a randomized, open‑label study in adults with ER+/HER2- advanced or metastatic disease whose cancer had progressed after one or two prior hormone therapies, including a CDK4/6 inhibitor. People received daily Veppanu by mouth or fulvestrant by injection. The main goal was how long people lived without the cancer growing, as reviewed by an independent group. In tumors with ESR1 mutations, Veppanu kept cancer from growing longer than fulvestrant. Median time without growth was about five months with Veppanu versus about two months with fulvestrant. The risk of the cancer getting worse or death was lower with Veppanu (hazard ratio 0.57). More people also had tumor shrinkage with Veppanu than with fulvestrant (overall response rate 19% vs. 4%). At the time of review, overall survival results were not ready because few deaths had occurred. Common side effects included low white blood cell counts, low red blood cell counts, fatigue, nausea, muscle or bone pain, constipation, reduced appetite, and changes in liver test results. Some people had changes in heart rhythm (QTc prolongation) and low potassium. The prescribing information carries warnings for heart rhythm problems and possible harm to a fetus. The study did not include everyone. People who had chemotherapy for advanced or metastatic disease or prior fulvestrant were not enrolled. Those whose cancer worsened very early on their last hormone therapy were also excluded. These limits are important when you and your health care provider consider how the results apply to you.
What Do I Need to Know?
The usual dose is 200 milligrams once daily with food. Swallow the tablets whole. Do not crush, split, dissolve, or chew them. You will typically continue until your cancer grows again or side effects become too strong.
You will need an FDA‑authorized test to confirm an ESR1 mutation before starting Veppanu. Your health care provider will order this test.
Veppanu can affect your heart rhythm. Your health care provider will check an electrocardiogram (ECG) and your blood potassium and magnesium before treatment and as needed during therapy. Try to avoid other medicines that can prolong the QT interval unless your health care provider decides they are necessary and can monitor you closely.
Veppanu can harm a fetus. If you can become pregnant, use effective birth control during treatment and for two weeks after the last dose. If you are a male with a partner who can become pregnant, also use effective birth control during treatment and for two weeks after the last dose. Ask your health care provider which methods are best for you.
Some medicines can raise Veppanu levels and increase side effects. Tell your health care provider and pharmacist about all medicines you take. Avoid strong CYP3A inhibitors unless your health care provider changes your dose. Do not take St. John’s wort, and avoid grapefruit and grapefruit juice while on Veppanu.
The companies developing Veppanu plan to work with a third‑party partner to help make it available. Ask your pharmacist about when it may be in stock and what your insurance might cover. Talk with your health care provider about how this medicine fits with your past hormone therapy and other treatments for ER+/HER2- breast cancer with an ESR1 mutation.